Claims for Patent: 9,352,037

Summary for Patent: 9,352,037

Title:	Compositions and methods to enhance the immune system
Abstract:	The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host\'s immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host\'s immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
Inventor(s):	van den Berg; Timo Kars (Amsterdam, NL)
Assignee:	STICHTING SANQUIN BLOEDVOORZIENING (Amsterdam, NL)
Application Number:	14/153,714
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,352,037
Patent Claims:	1. A composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against a cancer cell, wherein said therapeutic compound is a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody induces antibody-dependent cellular cytotoxicity (ADCC), and wherein the therapeutic antibody is selected from the group consisting of rituximab, herceptin, trastuzumab, alemtuzumab, bevacizumab, cetuximab and panitumumab, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha., wherein said agent is an anti-CD47 antibody or an anti-SIRP.alpha. antibody or a Fab fragment, a F(ab')2 fragment or a scFv fragment thereof. 2. A method of enhancing in vivo efficacy of a therapeutic antibody to induce cancer cell destruction by ADCC in a subject receiving anti-cancer treatment with a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody induces antibody-dependent cellular cytotoxicity (ADCC), said method comprising administering to said subject prior to, simultaneously or after the administration of the therapeutic antibody, an agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha., wherein the agent is in an amount sufficient to increase ADCC such that the in vivo efficacy of the therapeutic antibody to induce cancer cell destruction by ADCC is enhanced, and wherein said agent is an anti-CD47 antibody or an anti-SIRP.alpha. antibody or a Fab fragment, a F(ab')2 fragment or a scFv fragment thereof.

Details for Patent 9,352,037

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-04-23
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-04-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-04-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-04-23
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2028-04-23